Anavex Life Sciences Corp (AVXL)

[XenaLives]

See additional references at the right of this paper, there are seven more pages:

Send to
Links from PubMed
Items: 1 to 20 of 146<< First< PrevPage
1
of 8Next >Last >>
Select item 26606130
1.
AF710B, a Novel M1/s1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease.

Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, Brandeis R, Elkon H, Nahum V, Gershonov E, LaFerla FM, Medeiros R.

Neurodegener Dis. 2016;16(1-2):95-110.

PMID: 26606130 Free PMC Article
Similar articles



Select item 12212772
2.
AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53.

PMID: 12212772
Similar articles

Select item 14501019
3.
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R.

J Mol Neurosci. 2003;20(3):349-56. Review.

PMID: 14501019
Similar articles

Select item 18220527
4.
M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.

Fisher A.

Curr Alzheimer Res. 2007 Dec;4(5):577-80. Review.

PMID: 18220527
Similar articles

Select item 29291374
5.
AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease.

Hall H, Iulita MF, Gubert P, Flores Aguilar L, Ducatenzeiler A, Fisher A, Cuello AC.

Alzheimers Dement. 2018 Jun;14(6):811-823. doi: 10.1016/j.jalz.2017.11.009. Epub 2017 Dec 29.

PMID: 29291374
Similar articles

Select item 18322400
6.
M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.

Fisher A.

Neurodegener Dis. 2008;5(3-4):237-40. doi: 10.1159/000113712. Epub 2008 Mar 6. Review.

PMID: 18322400
Similar articles

Select item 2019998
7.
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.

Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R, Sapir M, Levy A, Heldman E.

J Pharmacol Exp Ther. 1991 Apr;257(1):392-403.

PMID: 2019998
Similar articles

Select item 17719699
8.
Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.

Chandra JN, Malviya M, Sadashiva CT, Subhash MN, Rangappa KS.

Neurochem Int. 2008 Feb;52(3):376-83. Epub 2007 Jul 10.

PMID: 17719699
Similar articles

Select item 16504943
9.
M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM.

Neuron. 2006 Mar 2;49(5):671-82.

PMID: 16504943 Free Article
Similar articles

Select item 25573298
10.
The effects of sigma (s1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice.

Malik M, Rangel-Barajas C, Sumien N, Su C, Singh M, Chen Z, Huang RQ, Meunier J, Maurice T, Mach RH, Luedtke RR.

Br J Pharmacol. 2015 May;172(10):2519-31. doi: 10.1111/bph.13076. Epub 2015 Apr 10.

PMID: 25573298 Free PMC Article
Similar articles

Select item 19835892
11.
AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW.

Neuropharmacology. 2010 Feb;58(2):365-73. doi: 10.1016/j.neuropharm.2009.10.003. Epub 2009 Oct 14.

PMID: 19835892
Similar articles

Select item 28944835
12.
Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model.

Li Z, Jia K, Duan Y, Wang D, Zhou Z, Dong S.

Mol Med Rep. 2017 Nov;16(5):7835-7840. doi: 10.3892/mmr.2017.7502. Epub 2017 Sep 18.

PMID: 28944835
Similar articles

Select item 28230352
13.
Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model.

Lebois EP, Schroeder JP, Esparza TJ, Bridges TM, Lindsley CW, Conn PJ, Brody DL, Daniels JS, Levey AI.

ACS Chem Neurosci. 2017 Jun 21;8(6):1177-1187. doi: 10.1021/acschemneuro.6b00278. Epub 2017 Mar 7.

PMID: 28230352 Free PMC Article
Similar articles

Select item 14501021
14.
Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors.

Lazareno S, Popham A, Birdsall NJ.

J Mol Neurosci. 2003;20(3):363-7.

PMID: 14501021
Similar articles

Select item 21558436
15.
Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.

Watt ML, Schober DA, Hitchcock S, Liu B, Chesterfield AK, McKinzie D, Felder CC.

J Pharmacol Exp Ther. 2011 Aug;338(2):622-32. doi: 10.1124/jpet.111.182063. Epub 2011 May 10.

PMID: 21558436 Free Article
Similar articles

Select item 11128032
16.
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.

Fisher A.

Jpn J Pharmacol. 2000 Oct;84(2):101-12. Review.

PMID: 11128032 Free Article
Similar articles

Select item 19595599
17.
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.

Malviya M, Kumar YC, Mythri RB, Venkateshappa C, Subhash MN, Rangappa KS.

Bioorg Med Chem. 2009 Aug 1;17(15):5526-34. doi: 10.1016/j.bmc.2009.06.032. Epub 2009 Jun 21.

PMID: 19595599
Similar articles

Select item 25800972
18.
The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model.

Puri V, Wang X, Vardigan JD, Kuduk SD, Uslaner JM.

Behav Brain Res. 2015;287:96-9. doi: 10.1016/j.bbr.2015.03.029. Epub 2015 Mar 20.

PMID: 25800972
Similar articles

Select item 26476132
19.
DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice.

Yang RY, Zhao G, Wang DM, Pang XC, Wang SB, Fang JS, Li C, Liu AL, Wu S, Du GH.

Pharmacol Biochem Behav. 2015 Dec;139(Pt A):15-26. doi: 10.1016/j.pbb.2015.10.009. Epub 2015 Oct 22.

PMID: 26476132
Similar articles

Select item 12212769
20.
Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.

Lazareno S, Popham A, Birdsall NJ.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):123-7.

PMID: 12212769
Similar articles

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803577/